Towards the lowest efficacious dose (toledo): results of a multicenter non-inferiority randomized open-label controlled trial assessing tocilizumab or abatacept injection spacing in rheumatoid arthritis patients in remission
Language
EN
Autre communication scientifique (congrès sans actes - poster - séminaire...)
This item was published in
EULAR 2019, EULAR 2019, 2019-06-12, Madrid. 2019-06